| Field | Specification |
|---|---|
| Mfr No | |
| Assay Time | |
| Assay Type | |
| Detection Method | |
| Gene ID | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | Serum Plasma |
| Storage | |
| Target |
Background
Anti-PEG antibody ELISA (mouse IgG specific) is a biological molecule commonly studied in life science research. Immunoglobulins are antibody proteins central to humoral immunity and antigen-specific responses.
Biological context
Researchers often monitor Anti-PEG antibody ELISA (mouse IgG specific) in Serum Plasma to better understand themes such as mechanistic biology studies, biomarker-focused profiling, and disease-model research. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in Anti-PEG antibody ELISA (mouse IgG specific) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, complementary pathway markers and controls appropriate to the biological model) and by keeping pre-analytical variables consistent across groups.
Why quantitative measurements are widely used
Quantitative immunoassays are widely used for measuring proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Anti-PEG antibody ELISA (mouse IgG specific) participates in.
Why is measuring anti-PEG antibodies important in biopharmaceutical research?
Polyethylene glycol (PEG) is widely used to extend the half-life of therapeutic proteins, peptides, and nanoparticle drug carriers (e.g., liposomes, mRNA-LNP vaccines). Pre-existing or induced anti-PEG antibodies (APAs) can cause accelerated blood clearance (ABC) of PEGylated drugs, reduce therapeutic efficacy, and in some cases trigger hypersensitivity reactions. Screening for APAs before and during treatment is increasingly recommended in preclinical and clinical studies.
What isotype does this kit specifically detect?
This kit is configured for isotype-specific detection and measures only the isotype stated in the product name (IgG or IgM, human or mouse). Isotype selectivity is achieved through a species- and class-specific secondary antibody conjugated to HRP. To profile a full APA response (IgG + IgM), both kits should be run in parallel on the same sample set.
How prevalent are pre-existing anti-PEG antibodies in naive populations?
Published studies using competitive ELISA methods have detected pre-existing anti-PEG antibodies in 55–99% of treatment-naïve blood donors, depending on the assay sensitivity and cohort studied (Verhoef et al., Anal Chem 2016; PMID: 27804292). The majority are at low levels, but a small subset of individuals carry high-titer APAs that may be clinically relevant. This underscores the importance of baseline APA screening before administering PEGylated therapeutics.
What sample types can be used with this kit?
This kit is validated for human serum and plasma (IgG/IgM human versions) or mouse serum and plasma (mouse IgG/IgM versions). EDTA and heparin plasma are acceptable. Samples should be diluted into assay buffer at the recommended MRD to minimize non-specific binding. Strongly hemolyzed or lipemic samples may require pre-clarification by centrifugation before assay.
What controls and standards are included in the kit?
Each kit includes: a recombinant anti-PEG monoclonal antibody positive control (calibrated in ng/mL), a negative control (naive serum/plasma), assay diluent, PEG-coated microplate, and HRP-conjugated secondary antibody. Standards allow expression of results in ng/mL rather than relative OD units, enabling cross-assay and cross-laboratory comparisons.
Is this kit suitable for mouse preclinical immunogenicity studies?
Yes — the mouse IgG and mouse IgM versions of this kit are specifically designed for preclinical rodent immunogenicity studies. They are used to monitor anti-PEG immune responses in mice receiving PEGylated drugs or nanoparticle formulations, in line with FDA guidance on immunogenicity testing for biopharmaceuticals.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- “Optimized ELISA for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin.” Frontiers in Immunology, 2025.
- “Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population.” Analytical Chemistry, 2016. PMID: 27804292
- “A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum.” Journal of Immunological Methods, 2019. PMID: 31614128